A groundbreaking new treatment for advanced pancreatic cancer has been approved by the FDA, providing a potential lifeline for patients battling one of the deadliest forms of the disease. The once-daily oral medication, developed by Revolution Medicines, marks a significant advancement in targeted therapy for those whose cancer has progressed despite prior treatments. Known as daraxonrasib and marketed under the brand name Rasonque, the drug represents the first FDA-approved option specifically designed to address a key genetic mutation linked to pancreatic tumors. For eligible patients, this approval introduces a new standard of care with the potential to extend survival in a cancer type notorious for its aggressive progression.
The Food and Drug Administration (FDA) on Wednesday approved a treatment for advanced pancreatic cancer, offering new life-extending care for patients with one of the most aggressive forms of cancer. The once-daily pill, called daraxonrasib and manufactured by Revolution Medicines, will be sold under the brand name Rasonque. It was approved for patients who already tried...
